Recursion: AI Hype Fizzles Amid Hard Clinical Truths [Seeking Alpha]
Exscientia Plc - American Depositary Shares (EXAI)
Company Research
Source: Seeking Alpha
Follow Summary Recursion's REC-994 met safety and tolerability endpoints in the Phase 2 trial for CCM, but efficacy data were limited. Secondary endpoints showed trends toward reduced lesion size in the highest dose group, though physician and patient-reported outcomes did not improve. Recursion's acquisition of Exscientia adds AI-driven drug discovery tools and an oncology/immunology pipeline but complicates the investment outlook. Recursion's financial position is stable, with $850 million in cash post-acquisition of Exscientia, providing a cash runway into 2027. Due to high operational costs and mixed clinical data, I recommend maintaining a "hold" on Recursion stock until more conclusive data emerges. Kevin Wells/iStock via Getty Images Introduction Nvidia-backed ( NVDA Recursion Pharmaceuticals' NASDAQ: RXRX ) stock is down 42% since my rating downgrade to "hold." In March, I expressed concern ahead of Phase 2 cerebral cavernous malformation [CCM] data pegged f
Show less
Read more
Impact Snapshot
Event Time:
EXAI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXAI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXAI alerts
High impacting Exscientia Plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
EXAI
News
- Recursion: No News Isn't Good News When It Comes To Vanilla Pipeline [Seeking Alpha]Seeking Alpha
- Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery [Yahoo! Finance]Yahoo! Finance
- AI in Healthcare Market to Grow by USD 20.34 Billion (2024-2028), Driven by Healthcare Digitization, AI-Powered Report Highlights Market Transformation - TechnavioPR Newswire
- Recursion and Exscientia Shareholders Approve the Proposed Combination [Yahoo! Finance]Yahoo! Finance
- Artificial Intelligence in Drug Discovery Market to Hit USD 6.89 Billion by 2029 with 29.9% CAGR | MarketsandMarkets™PR Newswire
EXAI
Earnings
- 8/15/24 - Miss
EXAI
Sec Filings
- 11/20/24 - Form S-8
- 11/20/24 - Form S-8
- 11/20/24 - Form 6-K
- EXAI's page on the SEC website